O-GlcNAc Engineering of GPCR Peptide-Agonists Improves Their Stability and in Vivo Activity-Reference-Cited by-同舟云学术

O-GlcNAc Engineering of GPCR Peptide-Agonists Improves Their Stability and in Vivo Activity

Published:2019-08-16 Issue:36 Volume:141 Page:14210-14219
ISSN:0002-7863
Container-title:Journal of the American Chemical Society
language:en
Short-container-title:J. Am. Chem. Soc.

Author:

Levine Paul M.^ORCID,Balana Aaron T.,Sturchler Emmanuel¹,Koole Cassandra²,Noda Hiroshi³,Zarzycka Barbara,Daley Eileen J.³,Truong Tin T.²,Katritch Vsevolod⁴^ORCID,Gardella Thomas J.³,Wootten Denise²,Sexton Patrick M.²^ORCID,McDonald Patricia¹,Pratt Matthew R.⁴^ORCID

Affiliation:

1. Department of Molecular Medicine The Scripps Research Institute, Jupiter, Florida 33458, United States

2. Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, VIC 3052, Australia

3. Endocrine Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02114, United States

4. Bridge Institute, University of Southern California, Los Angeles, California 90089, United States

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

National Health and Medical Research Council

Scripps Research Institute

University of Southern California

National Institute of Arthritis and Musculoskeletal and Skin Diseases

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Subject